CNSY Cerenome, Inc.
Debt Financing ·
Cerenome, Inc. received initial funding under a senior secured facility of up to $20 million from 3i, LP, with royalty-based repayments. The company says its cash runway now reaches well into 2028.
Nasdaq confirmed compliance with both the $35 million market value standard and the $2.5 million equity standard. The bid price deadline moves to November 12, 2025.
Investors in a March 2025 private placement agreed to cancel all Series A warrants and cut Series B warrant shares to up to 35,536,380. Lincoln Park may buy up to $50.0 million of stock over 36 months.
Nasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan by July 21, 2025, and any exception could run until November 17, 2025.
The company filed an NT 10-Q on May 15, 2025. It needs more time to account for warrants from a March 2025 private placement and expects lower stockholders' equity at March 31, 2025.
The company needs more time to finalize accounting for common stock purchase warrants issued in its March 2025 private placement. It expects a warrant liability that will lower stockholders' equity.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $5.2 million | $5.8 million |
| Research and development | $8.4 million | $10.6 million |
| Net income (loss) | -$22.4 million | -$13.0 million |
| Cash from operations | -$20.8 million | -$10.6 million |
| Cash and equivalents | $4.3 million | $76,000 |
| Short-term investments | $4.4 million | $3.5 million |
Our latest story on this, dated Jun 17, 2025: "Plus Therapeutics (now Cerenome) cancels warrants, signs $50 million Lincoln Park deal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 23, 2025: "Plus Therapeutics (now Cerenome) gets Nasdaq deficiency notice over late Form 10-Q". The story links the filing or release it is based on. Read the story.
Cerenome, Inc. trades under the ticker CNSY on NASDAQ.
Cerenome, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Cerenome, Inc. is 1095981. Its filings are on SEC EDGAR.
7,589,625 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Cerenome, Inc. under United States.
Our directory classifies Cerenome, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cerenome, Inc. is US72941H8060.
aibio.space lists Cerenome, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$5.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Cerenome, Inc. reported a net loss of $22.4 million for the fiscal year ended Dec 31, 2025, and used $20.8 million of cash in operations, per its annual report to the SEC.
$8.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$8.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a financing. SEC Form S-3. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio